European Journal of Dermatology
MENUConsiderations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases Volume 31, numéro 3, May-June 2021
Auteurs
1 Section of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
2 Dermatology Unit, San Martino Policlinic Hospital IRCCS, Genoa, Italy
3 Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy
4 Section of Public Health, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
5 Hygiene Unit, San Martino Policlinic Hospital IRCCS, Genoa, Italy
- DOI : 10.1684/ejd.2021.4043
- Page(s) : 415-7
- Année de parution : 2021
Patients affected by autoimmune bullous diseases (AIBDs) are fragile due to immunosuppressive treatment. Infections, favoured by immunosuppression, represent an important cause of death in AIBD patients [1]. No specific dermatological guidelines address the SARS-CoV-2 vaccination issue in AIBD patients [1]. According to general guidelines for AIBD management, patients receiving immunosuppressive therapy should receive non-live vaccinations (e.g. against seasonal influenza, pneumococcal infection), [...]